【研报掘金丨华创证券:维持迈瑞医疗“推荐”评级,国际市场持续发力】华创证券研报指出,迈瑞医疗(300760.SZ)24年归母净利润116.68亿元(+0.74%),25Q1归母净利润26.29亿元(-16.81%)。分区域看,24年国际市场全年增长21.28%。25Q1持续承压,有望逐季度改善。随着2025年以来地方财政资金紧张的缓解、医疗专项债发行规模的反弹、发改委主导的医疗设备更新项目启动,预计国内市场将于今年Q3增速回正,实现反弹。根据DCF模型测算,给予公司整体估值3371亿元,目标价约278元,对应2025年PE 为27X,维持“推荐”评级。

金融界
20 May
华创证券研报指出,迈瑞医疗(300760.SZ)24年归母净利润116.68亿元(+0.74%),25Q1归母净利润26.29亿元(-16.81%)。分区域看,24年国际市场全年增长21.28%。25Q1持续承压,有望逐季度改善。随着2025年以来地方财政资金紧张的缓解、医疗专项债发行规模的反弹、发改委主导的医疗设备更新项目启动,预计国内市场将于今年Q3增速回正,实现反弹。根据DCF模型测算,给予公司整体估值3371亿元,目标价约278元,对应2025年PE 为27X,维持“推荐”评级。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10